Development asset linked to Lupin (Europe) in public FDA and regional records.
pharma · Myotonic Dystrophy type 1 and type 2 (DM1/DM2) · Non-Dystrophic Myotonias (NDM)
Lupin (Europe)
Lupin Europe GmbH
Lupin (Europe) drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
37 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Employees
- 37
- Programs
- 4
- Drugs
- 9
- Patents
- 0
Lupin (Europe) pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lupin (Europe) drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Lupin (Europe) in public FDA and regional records.
-
Development asset linked to Lupin (Europe) in public FDA and regional records.
-
Development asset linked to Lupin (Europe) in public FDA and regional records.
-
mexiletine hcl
Cardiovascular system (C01)Cardiovascular system (C01) compound in Lupin (Europe)'s portfolio. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Lupin (Europe) in public FDA and regional records.
-
Development asset linked to Lupin (Europe) in public FDA and regional records.
-
Development asset linked to Lupin (Europe) in public FDA and regional records.